Most advanced review on non-lipid-regulating action of atorvastatin

Abstract

Abstract: Recent reports have indicated that Statins could remarkably improve the prognosis of patients suf- fered from coronary artery disease .And this effect is not only due to Statin' s lipid-regulating function, but also correlated to its non-lipid-regulating action .Atorvastatin is the latest kind of statins .In this article, we specified the non-lipid-regulating effect of Atorvastatin in the preven- tion and therapy to coronary artery disease .Furthermore, we summarized its corresponding clinical evaluation or se- curity .

Key words: Atorvastatin , non-lipid-regulating ef- fect , coronary artery disease , inflammation , security

CLC Number:

R966

SUN shan, WU Shang-qin. Most advanced review on non-lipid-regulating action of atorvastatin[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(2): 141-144.

References 30

1	Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis [ J] . Circulation, 2002; 105: 1135 -43
2	Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methyl- glutaryl coenzyme a reductase inhibitors[ J] . Arterioscler Thromb Vasc Biol, 2001; 21 : 1712-9
3	Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid- related effects of statins[ J] . Ann Med, 2000 ; 32: 164-76
4	Shah PK, Falk E, Badimon JJ .Human monocyte-derived mac- rophages induce collagen breakdown in fibrous caps of athero- sclerotic plaques . Potential role of matrix-degrading metallopro- teinases and implications for plaque rupture [ J] .Circulation, 1999 ; 92: 1565-9
5	Tziakas DN, Chalikias GK, Parissis JT, Hatzinikolaou EI, Pap- adopoulos ED, Tripsiannis GA, et al .Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes, The effects of short-term atorvastatin admin- istration[ J] . Int J Cardiol, 2004; 94 : 269-77
6	Hwang YS, Tsai WC, Lu YH, Lin CC, Chen YF.Effect of Atorv- astatin on the expression of CD40 ligand and p-selectin on plate- lets in patients with hypercholesterolemia[ J] .Am J Cardiol, 2004 ; 94: 364 -6
7	沈敏, 李兰荪.阿托伐他汀对不稳定型心绞痛患者 C 反应蛋白及细胞粘附分子的影响[ J] .临床内科杂志, 2003; 20: 74-6
8	许竹梅, 赵水平, 聂赛, 周宏年, 李全忠, 刘玲.阿托伐他汀增加单核细胞过氧化物酶增殖体激活受体γ表达改善炎症反应[ J] .中华心血管病杂志, 2004; 32 : 329-33
9	Burleigh ME, Babaev VR, OatesJA, Harris RC,Gautam S, Rien- deau D, et al .Cy clooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-2 deficient mice[ J] .Circula- tion, 2002; 105 : 1816-23
10	赵水平, 邓平, 吴洁, 周宏年, 聂赛.阿托伐他汀短期治疗对急性冠状动脉综合征外周血单核细胞环氧化酶 2 信使核糖核酸表达的影响[ J] .中国循环杂志, 2005; 20 : 165-8
11	Verschuren L, Kleemann R, Offerman EH, Szalai AJ, Emeis SJ, Princen HM, et al . Effect of low dose atorvastatin versus diet-in- duced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein e ＊3-leiden transgenic mice [ J] . Arterioscler Thromb, 2005; 25 : 161-7
12	Pasceri V, Wu HD, Willerson JT, Yeh ET.Modulation of vascu- lar inflammation in vivo and in vitro by peroxisome prolifera- tors2activator2γ activators[ J] . Circulation, 2000; 101 : 235-8
13	赵水平, 张大庆, 周宏年, 聂赛, 李全忠.阿托伐他汀对脂肪细胞分泌白细胞介素 6 的影响[ J] .中华内科杂志, 2003 ; 42: 874 -5
14	Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al . Pravastatin and the development of diabetes mellitus:evi- dence of a protective treatment effect in the west of scotland cor- onary prevention study[ J] . Circulation, 2001; 103 : 357 -62
15	Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabol- ic factors, inflammatory markers, and vascular reactivity in dia- betic patients and subjects at risk for diabetes[ J] .Diabetes Care, 2004; 27: 2450 -7
16	Atalar E, Ozmen F, Haznedaroglu I, Acil T, Ozer N, Ovunc K, et al .Effects of short-term atorvastatin treatment on global fibrino- lytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease[ J] .Int J Cardiol, 2002; 84: 227-31
17	李洁琪, 赵水平, 方颖, 吴立荣, 李屏.阿托伐他汀对培养的兔脂肪细胞凝血和纤溶因子的影响及其机制[ J] .中国循环杂志, 2005; 20 : 221-4
18	袁晓华, 张蕴.超常规量阿托伐他汀对急性心肌梗死患中国临床药理学与治疗学 2006 Feb; 11( 2) · 143 ·者早期血管内皮功能的影响[ J] .天津医科大学学报, 2004; 10 : 170-2
19	范伯丽, 程颖, 房家智, 蒋宝琦, G Neil Thomas, Julian AJH Critchley, 等.阿托伐他汀对高脂血症患者血小板聚集反应的影响[ J] .中国动脉硬化杂志, 2003; 11: 455 -8
20	Li DY, Chen HJ,Mehta JL. Statins inhibit oxidized-LDL-mediat- ed LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation[ J] . Cardiovasc Res, 2001; 52 : 130-5
21	Zhao SP, Zhang DQ.Atorvastatin enhances cellular uptake of oxidized LDL in adipocytes from hypercholesterolemic rabbits [ J] . Clinica Chimica Acta, 2004 ; 339 : 189-94
22	Fuhrman B, Koren L, Volkova N, Keidar S, Hayek T, Aviram M.Atorvastatin therapy in hypercholesterolemic patients sup- presses cellular uptake of oxidized-LDL by differentiating mono- cytes[ J] . Atherosclerosis, 2002; 164 : 179-85
23	Giuseppe M, Sandra Z, Francesca S.Effect of Atorvastatin on endothelium-dependent vasodilation in postmenopausal women with average serum cholesterol levels[ J] . Am J Cardiol, 2002 ;
90	: 747 -50
24	陈斌, 邓玉莲, 吴志勇, 高美钦, 郑伟, 黄爱民.阿托伐他汀对兔动脉粥样硬化模型血管壁平滑肌细胞凋亡的影响 [ J] .中国老年学杂志, 2004; 24: 542 -4
25	Carlos G, Luis M, Blanco C,Monica O. 3-hydroxy-3- methylglu- taryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth musclecells in culture [ J] .Circ Res, 1998; 83: 490 -500
26	Harvey S, Hecht S, Mitchell H .Comparison of the effects of atorvastatin versus simvastatin on subclinical atherosclerosis in primary prevention as determined by electron beam tomography [ J] . Am J Cardiol, 2003; 91: 42 -5
27	Sweder WE, Dianne JM .Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque de- velopment in APOE＊3 Leiden transgenic mice[ J] . Atheroscle- rosis, 2002 ; 164: 65-71
28	Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of atorv- astatin derived from analysis of 44 completed trials in 9, 416 pa- tients[ J] . Am J Cardiol, 2003 ; 92: 670-6
29	陈雯艾, 陈君柱, 胡晓晟, 朱建华, 冯立民, 姚雪艳.阿托伐他汀治疗原发性高脂血症的疗效和安全性[ J] .中华心血管病杂志, 2003; 31 : 577
30	Terry AJ .Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome p450 inhibitors[ J] .Am J Cardiol, 2004;94: 1140 -6

[1]	LIAO Mengling, WANG Yan, LUO Jing, WANG Nuoyan, HUA Ling, ZHANG Yu, DENG Fei, YUAN Yue, ZHOU Jun, ZHOU Hong. Molecular mechanism of artesunate attenuates the release of proinflammatory cytokines from macrophages [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 969-978.
[2]	ZHAO Lingzhi, HE Yanjun, XIE Jianqin, YOU Chongge. Research progress on therapeutic role of recombinant human soluble thrombomodulin in atherosclerosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 832-840.
[3]	LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
[4]	LIANG Hongyu, ZHANG Hailin, YIN Huanxin, CHEN Fan, LU Junlin, ZHU Caihong, HU Wei, ZHOU Renpeng. Effects of 2-APB in skin wound healing in mice through down-regulation of TRPM7 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 747-753.
[5]	LIANG Meifang, CHEN Qingzhuang, YANG Peiqun, WANG Yong. Efficacy and safety of generic and branded atorvastatin in patients with ischemic stroke/transient ischemic attack: A real-world study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 785-792.
[6]	MAO Shuying, JIN Wei, FU Sisi, LIU Keanqi, ZHOU Zhihao, WANG Guangji, LIANG Yan. Oral lienal peptides improve ammonia-induced coughing and inflammation in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 601-607.
[7]	JIN Yiyi, ZHOU Keting, YANG Chengcheng, XU Ping, ZHU Suyan. Osthole attenuates diabetes-induced renal injury by regulating NF-κB and p38/MAPK pathway mediated inflammatory responses [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 622-631.
[8]	CHANG Shufu . Progress of medical treatment of coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 405-408.
[9]	WEI Jifang, YUE Hongmei, LIU Nanyu, SONG Peipei, XIE Yingying, WANG Jiaqi, WEI Yaqian. Research progress on the relationship between thyroid hormone and idiopathic pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 307-313.
[10]	CHEN Yu, GU Bing, LI Huanan. Modulating gut miocrobiota: a new strategy in the treatment of gout [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1307-1314.
[11]	CHEN Yugang, TU Yanqiong, WANG Congqing, CHEN Juan, ZHANG Bohong. Network pharmacology and molecular docking to discuss the mechanism of Jinhutongdan prescription in the treatment of cholelithiasis and experimental verification [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1090-1098.
[12]	LI Ying, YAO Wei, WANG Meng, YU Zhihong, GONG Yuanqi, LAN Haibing, QI Xiefei. Experimental study of irisin alleviates house dust mite-induced airway epithelial cells inflammation and apoptosis via the NF-κB and JNK signaling pathways [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1106-1112.
[13]	WU Lin, HAO Yingxiang, ZHANG Lei, ZHANG Tianxue, GAO Mingjing, LENG Yufang. Paricalcitol attenuates intestinal ischemia-reperfusion injury in mice through HMGB1/TLR4/NF-κB signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 1-7.
[14]	WANG Rui, PAN Jinjin, LI Hua, YUAN Yuhui. Research progress of melatonin on pulmonary hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 444-448.
[15]	FANG Qiujue, WANG Zhaojun, YUAN Wei, DING Shu, WANG Zhongqun. Correlation between soluble ST2 and coronary artery complex lesions and their severity [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 278-284.